BioSpace News Archive

Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108 PPM

Gives paramedics and EMTs rapid, secure access to life-saving medication history and secure communications with ER, doctors, and hospitals

The levels of inflammatory markers in PD patients treated with ANVS401 were significantly lower than before treatment.

GreenLight Biosciences today announced that they have acquired rights to portions of Bayer’s topical RNA Intellectual Property portfolio. These assets include bee health capabilities to protect against Varroa mites, a major threat to honeybees.

Data are a stark reminder that ET-related healthcare system costs are under-appreciated and underscore the potential of Cala Trio to address the needs of patients and payers

The Acessa® procedure is a minimally invasive treatment alternative to hysterectomy for women who have symptomatic fibroids

Kaku et al. Long-term efficacy and safety in Phase 3 study with Imeglimin as mono- and add-on therapy in Japanese T2DM patients: results from TIMES 2 trial Hata et al. Post hoc analysis of Phase 2 and 3 studies of Imeglimin – similar efficacy and consistent safety in patients with different backgrounds, including elderly patients and those with renal impairment

Lumenix is pleased to announce that the Federal Government of Canada has purchased its Artificially Intelligent Monitoring System for hand hygiene to deploy at The Ottawa Hospital, one of the largest teaching and research hospitals in Canada.

The most populous boroughs in New York City, Queens and Brooklyn, likely served as the major hub of COVID-19 spread in the spring of 2020, a new study finds.

Biogen Inc. (Nasdaq: BIIB) today announced that its next generation manufacturing facility in Solothurn, Switzerland has received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC).